Search Results

Abstract #256: Assessing Comprehensive Care Deficits in United States (US) Ovarian Cancer Programs to Inform Quality Improvement Initiatives Authors: Matthew Smeltzer1, Monique Dawkins2, Leigh Boehmer2, Sarah Madhu Temkin3, Premal H. Thaker4, Leigha Senter5, Anna Yemelyanova6, Michelle Bigg7, Jennifer Bires8, Sean Christopher Dowdy9, Anthony Magliocca10 1University of Memphis, School of Public …

Cancer programs of all types across the U.S. face similar challenges in providing quality care for women with ovarian cancer. Multiple stakeholders can contribute to QI solutions with a team approach and clear communication around quality gaps.

By Diane Mapes For the immunocompromised and those with disease, social distancing and uncertainty are a way of life. Daily walks, gratitude, and dancing help. You’re washing your hands like crazy. Staying six feet away from people with the sniffles. You don’t know if it’s safe to hug your friends or family, or go to work, or what. You don’t even know if you’ll be alive in a year. It’s scary. …

The Inherited Cancer Registry (ICARE) is an academic-community partnership among healthcare providers, researchers, and individuals at an increased risk for inherited cancer. Learn about ICARE’s research registry for high-risk individuals and education efforts on inherited cancer for both patients and providers.

OI | July-August 2014 | www.accc-cancer.org 29 Improving Access to Oncology Genetic Counseling While only 5 to 10 percent of cancer diagnoses are associated with a hereditary syndrome, many of these syndromes have an alarmingly high lifetime risk of cancer—approaching 80 to 100 percent, with development of disease at younger ages than in the general population.1-3 Recent advancements …

Ovarian cancer ranks fifth in cancer deaths among U.S. women. At the early stages of this disease many women are asymptomatic or experience symptoms attributable to other health issues.

34 Oncology Issues January/February 2009 All women face some risk, but the likelihood of developing breast or ovarian cancer is much higher in those who carry an alteration in the BRCA1 or BRCA2 gene. For these women, the lifetime risk of developing breast cancer is as high as 85 percent, and cancer can occur at a much younger age. Depending on which gene alterations a woman carries, her …

G enetic testing for hereditary breast cancer has been available since BRCA1 and BRCA2, the genes that cause hereditary breast and ovar- ian cancer syndrome (HBOC), were discov- ered in 1994 and 1995.3 Females with BRCA1 and/or BRCA2 mutations have as high as a 40 to 87 per- cent lifetime risk of breast cancer and a 15 to 45 percent lifetime risk of ovarian cancer.4,5 In addition, women with …